Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation

• US 9,394,307 B2
• Filed: 10/01/2013
• Issued: 07/19/2016
• Est. Priority Date: 07/12/2007
• Status: Active Grant

• Current Assignee: ChemoCentryx, Inc. (Amgen Inc.)
• Original Assignee: ChemoCentryx, Inc. (Amgen Inc.)
• Inventors: Krasinski, Antoni, Punna, Sreenivas, Ungashe, Solomon, Wang, Qiang, Zeng, Yibin
• Primary Examiner(s): Murray, Jeffrey H
• Application Number:
  US14/043,602
• Publication Number:
  US 20140100237A1
• Time in Patent Office: 1,022 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: A61P 31/06 for tuberculosis
• CPC Class Codes: C07D 213/79 Acids; Esters
• CPC Class Codes: C07D 213/81 Amides; Imides
• CPC Class Codes: C07D 213/84 Nitriles
• CPC Class Codes: C07D 471/04 Ortho-condensed systems
• CPC Class Codes: C07D 471/12 in which the condensed system contains three hetero rings
• CPC Class Codes: C07D 473/00 Heterocyclic compounds containing purine ring systems
• CPC Class Codes: C07D 487/04 Ortho-condensed systems

Abstract

Compounds are provided that act as potent antagonists of the CCR2 receptor. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases and as controls in assays for the identification of CCR2 antagonists.

Claims

1. A method of treating a CCR2-mediated condition or disease, comprising administering to a subject a therapeutically effective amount of a compound of the formula (I) or a pharmaceutically acceptable salt thereof:

2. The method of claim 1, wherein said CCR2-mediated condition or disease is atherosclerosis.

3. The method of claim 1, wherein said CCR2-mediated condition or disease is restenosis.

4. The method of claim 1, wherein said CCR2-mediated condition or disease is multiple sclerosis.

5. The method of claim 1, wherein said CCR2-mediated condition or disease is selected from the group consisting of inflammatory bowel disease, renal fibrosis, and rheumatoid arthritis.

6. The method of claim 1, wherein said CCR2-mediated condition or disease is type 2 diabetes.

7. The method of claim 1, wherein said CCR2-mediated condition or disease is selected from the group consisting of chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and idiopathic pneumonia syndrome.

8. The method of claim 1, wherein the CCR2-mediated condition or disease is selected from the group consisting of obesity.

9. The method of claim 1, wherein the CCR2-mediated condition or disease is noninsulin dependent diabetes.

10. The method of claim 1, further comprising administering a therapeutically effective amount of a second therapeutic agent.

11. A method of treating a CCR2-mediated condition or disease, comprising administering to a subject a therapeutically effective amount of a compound of the formula

12. The method of claim 11, wherein said CCR2-mediated condition or disease is restenosis.

13. The method of claim 11, wherein said CCR2-mediated condition or disease is multiple sclerosis.

14. The method of claim 11, wherein said CCR2-mediated condition or disease is selected from the group consisting of inflammatory bowel disease, renal fibrosis, and rheumatoid arthritis.

15. The method of claim 11, wherein said CCR2-mediated condition or disease is type 2 diabetes.

16. The method of claim 11, wherein said CCR2-mediated condition or disease is selected from the group consisting of chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and idiopathic pneumonia syndrome.

17. The method of claim 11, wherein the CCR2-mediated condition or disease is selected from the group consisting of obesity.

18. The method of claim 11, wherein the CCR2-mediated condition or disease is selected from the group consisting of noninsulin dependent diabetes.

19. The method of claim 11, further comprising administering a therapeutically effective amount of a second therapeutic agent.